From Genomics to Healthspan: Dr. Wei-Wu He’s Vision for Preventing Disease

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Wei-Wu, Executive Chairman at Human Longevity, Inc. Together, they explore how advances in genome sequencing, AI, and multi-layered diagnostics are changing the fight against age-related diseases. Wei-Wu shares why understanding your own genetic risks and combining them with other health data leads to better prevention and a longer healthspan.Wei-Wu explains the value of integrating genome sequencing, advanced imaging, and liquid biopsy to catch diseases like cancer early, before symptoms appear. He draws on real-world examples, including how combining different tests can spot cancers that single methods might miss. The conversation highlights how technology brings down costs, making once-rare insights widely available, and how each person stands to benefit from personalized risk profiles.The episode closes with practical advice: use today’s tools to become the CEO of your own health. Wei-Wu urges listeners to embrace data-driven, individualized care and stresses that no single tool or habit holds all the answers. Instead, true longevity comes from a holistic, ongoing approach, one that uses all available knowledge to prevent disease and extend both life and health.Guest-at-a-Glance💡 Name: Dr. Wei-Wu💡 What he does: Executive Chairman💡 Company: Human Longevity, Inc.💡 Noteworthy: Known for leading advances in genomics, precision medicine, and early disease detection by integrating AI, genome sequencing, and multi-omics data.💡 Where to find him: https://www.linkedin.com/in/wei-wu-he-ph-d-he-him-b6957313/ Episode highlights:[00:00:00]: Introduction[00:01:06]: Background in Genomics and Precision Medicine[00:04:13]: Early Influences and Motivation for Longevity Research[00:06:12]: Lessons from a Longevity Mentor[00:08:11]: Academic Journey and Early Biomarker Research[00:09:18]: Transition from Academia to Industry[00:10:40]: Breakthroughs in Biomarker Approval and Commercialization[00:11:15]: Connecting Genotype and Phenotype[00:11:49]: Human Genome Sequencing: Cost and Innovation[00:13:28]: Shotgun Sequencing and the Race to Decode the Genome[00:14:39]: Linking Genes to Disease Risk[00:15:39]: Advances in Genome Sequencing Technology[00:16:56]: Biomarkers for Early Cancer Detection[00:18:49]: Improving Prostate Cancer Detection with Multi-Modal Data[00:20:30]: Personalized vs. Statistical Medicine[00:22:11]: The Symphony of Longevity Care[00:23:05]: Pap Smear and Cervical Cancer Screening[00:24:39]: Vaccination and Cancer Prevention Progress[00:26:00]: Global Disparities in Cancer Outcomes[00:27:07]: Translating Scientific Breakthroughs to Population Health[00:28:24]: The Value of Universal Genome Sequencing[00:29:18]: Impact of Monogenic Diseases and Newborn Screening[00:31:27]: Polygenic Risk Scores and Disease Prediction[00:34:47]: Evolving Genomic Knowledge and Ongoing Discovery[00:38:07]: The Case for Sequencing as a Lifelong Investment[00:44:30]: Cancer Prevention and the Titanic Analogy[00:50:08]: Multi-Modal Cancer Detection: Genetics, Imaging, and Liquid Biopsy[00:57:24]: Advances and Limits of Genome Sequencing Technology[00:58:10]: Liquid Biopsy for Early Cancer Detection[01:01:28]: Integrating Data for High-Accuracy Cancer Prediction[01:03:41]: Multi-Diagnostic Approach in Clinical Practice[01:07:49]: Quick-Fire Round: Personal Biomarkers and Longevity Habits[01:15:41]: The Myth of Single Solutions in Longevity[01:15:51]: Embracing Data-Driven Longevity and AI[01:19:59]: Closing Remarks and TakeawaysFor science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast